Skip to content
Screener

Other geography segments

US
$172.34M+3.2%
CN
$4.56M+1,425%

Similar metrics at other companies

Euronet Worldwide logo
EEFTFR — Revenue
$57.2M+9.0%
Our Bond, Inc. logo
OBAIFR — Revenue
$3.5K
Orthofix Medical Inc. logo
OFIXFR — Revenue
$3.27M+2.6%
Stepan logo
SCLFR — Revenue
$52.86M+22.1%
Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemNet Revenues / Three Months Ended / June 30, 2026Net Revenues / Three Months Ended / June 30, 2025Net Revenues / Six Months Ended / June 30, 2026Net Revenues / Six Months Ended / June 30, 2025Long-Lived Assets / June 30, 2026Long-Lived Assets / December 31, 2025
United States$172,342$167,002$331,382$329,592$247,218$206,697
China4,5602997,042380107,268110,055
France7,0017,11316,65014,97034,64036,967
Total$183,903$174,414$355,074$344,942$389,126$353,719

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's FR — revenue?
Amphastar Pharmaceuticals (AMPH) reported FR — revenue of $7M in Q2 2026.
How has Amphastar Pharmaceuticals's FR — revenue changed year-over-year?
Amphastar Pharmaceuticals's FR — revenue decreased by 1.6% year-over-year, from $7.11M to $7M.
What is the long-term trend for Amphastar Pharmaceuticals's FR — revenue?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's FR — revenue has grown at a 31.3% compound annual growth rate (CAGR), from $11.88M to $35.28M.
What does FR — revenue mean?
This metric represents the total gross sales generated by the specific geographic or product segment identified as FR. It reflects the market demand and commercial success of the company's offerings within this defined operational area. Monitoring this figure helps investors assess the growth trajectory and revenue contribution of this specific business unit relative to the company's total consolidated performance.

Ask your AI about Amphastar Pharmaceuticals's fr — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude